$57 Million is the total value of Knoll Capital Management, LLC's 18 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals HLDGS | $16,717,000 | +118.1% | 2,563,925 | 0.0% | 29.31% | +1079.6% | |
| ABEO | Abeona Therapeutics Inc | $8,036,000 | +150.4% | 1,359,767 | 0.0% | 14.09% | +1254.9% | |
| SYN | Synthetic Biologics Inc. | $6,609,000 | -1.7% | 3,734,149 | 0.0% | 11.59% | +432.0% | |
| VBLT | Vascular Biogenics LTD | $4,406,000 | +11.1% | 860,605 | 0.0% | 7.73% | +500.8% | |
| CEMP | Cempra Inc | $4,318,000 | +44.9% | 180,800 | 0.0% | 7.57% | +683.7% | |
| Advaxis Inc. | $2,857,000 | +28.4% | 275,000 | 0.0% | 5.01% | +594.9% | ||
| ADHD | Alcobra Ltd | $2,799,000 | -44.1% | 1,115,315 | 0.0% | 4.91% | +202.4% | |
| VNRX | Volition RX LTD | $2,575,000 | +77.1% | 461,538 | 0.0% | 4.52% | +858.6% | |
| AMPE | Sell | Ampio Pharmaceuticals Inc. | $2,081,000 | -50.2% | 2,738,322 | -15.4% | 3.65% | +169.5% |
| NLNK | Newlink Genetics Corp | $1,504,000 | +30.4% | 102,437 | 0.0% | 2.64% | +605.1% | |
| ALDX | Aldeyra Therapeutics Inc | $1,038,000 | +34.3% | 135,800 | 0.0% | 1.82% | +625.1% | |
| KERX | Keryx Biopharmaceuticals Inc. | $1,030,000 | -22.2% | 200,000 | 0.0% | 1.81% | +321.0% | |
| RTTR | New | Ritter Pharmaceuticals, Inc | $869,000 | – | 526,903 | +100.0% | 1.52% | – |
| Advaxis Inc.w exp 07/15/201 | $750,000 | +49.4% | 112,500 | 0.0% | 1.32% | +706.7% | ||
| OHRP | OHR Pharmaceutical Inc | $568,000 | +1.1% | 205,000 | 0.0% | 1.00% | +447.3% | |
| ORPN | Bio Blast Pharma Ltd | $424,000 | +5.5% | 250,970 | 0.0% | 0.74% | +471.5% | |
| CLBS | Sell | Caladrius Biosciences Inc | $266,000 | -18.9% | 55,781 | -90.0% | 0.47% | +339.6% |
| CSBR | Champions Oncology INC | $184,000 | -23.0% | 111,111 | 0.0% | 0.32% | +319.5% | |
| ZSAN | Exit | Zosano Pharma Corp | $0 | – | -11,195 | -100.0% | -0.01% | – |
| Exit | Aptose Biosciences Inc | $0 | – | -11,933 | -100.0% | -0.01% | – | |
| GLMD | Exit | Galmed Pharmaceuticals Ltd | $0 | – | -49,947 | -100.0% | -0.07% | – |
| EVOK | Exit | Evoke Pharma Inc | $0 | – | -55,660 | -100.0% | -0.12% | – |
| MDVN | Exit | Medivation, Inc. | $0 | – | -4,397,838 | -100.0% | -85.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.